Related Experiment Video
Updated: Jan 28, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Hypocomplementemic urticarial vasculitis and multiple Sclerosis: A rare association or an atypical presentation?
João Durães1, Margarida Gonçalo2, Lívia Sousa1
1Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra 3000-075, Portugal.
Multiple Sclerosis (MS) co-occurring with Hypocomplementemic Urticarial Vasculitis (HUV) presents diagnostic and management challenges. Rituximab stabilized both immune-mediated diseases in a complex case, highlighting the need for further research.
Area of Science:
- Neurology
- Immunology
- Rheumatology
Background:
- Multiple Sclerosis (MS) is linked to immune-mediated diseases, yet underlying mechanisms and clinical implications are under-explored.
- Concurrent autoimmune conditions complicate MS diagnosis and treatment strategies.
Observation:
- A case study details a patient diagnosed with MS at age 27, later developing Hypocomplementemic Urticarial Vasculitis (HUV) seven years later.
- Standard disease-modifying treatments for both MS and HUV provided limited benefit, with significant MS progression.
- Rituximab therapy ultimately stabilized disease activity in both conditions.
Findings:
- The co-occurrence of MS and HUV presents significant management difficulties, impacting therapeutic choices and adverse effect profiles.
- Hypotheses include central nervous system involvement in urticarial vasculitis or a direct association between MS and HUV.
Implications:
- Diagnosing MS in patients with concurrent immune-mediated diseases is challenging.
- Optimal management strategies for MS patients with co-existing autoimmune diseases require further investigation.
- More case reports are needed to clarify the relationship and management of MS and HUV.
Related Concept Videos
Self-Presentation
Self-Presentation: Self-Monitoring and Self-Handicapping
Strategies of Self-Presentation I: Strategic Self-Presentation
Processes of Self-Presentation
Antipsychotic Drugs: Typical and Atypical Agents
Strategies of Self-Presentation II: Self-Verification

